Etiology

• Recurrent periorbital swelling, beginning in adolescence, causing progressive loss of elasticity, periorbital skin redundancy, and lacrimal gland prolapse
• IgA-mediated autoimmune process, with IgA deposits around elastin fibers and blood vessels (Wang, Arch Dermatol 2009)
• Dermatochalasis is a term restricted to involutional change, with skin redundancy, frequently confused with blepharochalasis, a term specifically describing this condition of recurrent edema in adolescents (Tenzel, Arch Ophthalmol 1978).

Epidemiology

• Although uncommon, large case series have been reported.
• In 54 cases from Beijing, average age at onset was 9.3 years, duration of clinical disease was 2–16 years, stabilizing in later adolescence (Li, Chinese J Ophthalmol 2012).
• Most cases are sporadic, but some can show autosomal dominant inheritance.
• Female:male ratio is about 2:3.

History

Figure 1. Blepharochalasis. Courtesy Rona Z. Silkiss, MD, FACS.

• History more than physical exam helps establish the diagnosis with recurrent painless eyelid swelling, starting in adolescence, and poor response to antihistamine therapy (Wang, Arch Dermatol 2009).
• Primarily upper lids, but lower eyelids may be involved.
• Duration of acute edema ranges from hours to days, with an average of 2 days and spontaneous resolution.
• Edema episodes occur 3–4 times a year early in the disease, tend to occur less frequently with time, and eventually enter a quiescent phase.
• Each episode of swelling can be preceded by an apparent upper respiratory infection (Hallahan, Br J Ophthalmol 2012).

Clinical features

• Of 30 adolescents with blepharochalasis treated at Moorfields Eye Hospital in London, England, 14 were unilateral cases (Collin, OPRS 1991).
• Eyelid skin becomes atrophic, discolored, redundant, and wrinkled with recurrent attacks of inflammatory edema of the eyelids.
• Rather than prolapse, there is commonly atrophy of orbital fat related to recurrent inflammation.
• Other sequelae can include blepharoptosis, herniation of the lacrimal gland palpebral lobe, and increased eyelid vascularity.
• In late stages, dehiscence of the upper and lower lids from the medial and lateral tendons can lead to acquired blepharophimosis.

Testing

• Biopsy of eyelid yields characteristic findings:
• Atrophy, fragmentation, and decreased elastin fibers in the dermis.
• Epidermis can be atrophic or thinned.
• Perivascular infiltrates composed of lymphocytes, histiocytes, plasma cells, mast cells and occasional eosinophils
• Immunofluorescence: IgA antibodies directed against elastin fibers, without IgG or IgM
• In late phases, though there can be significant loss of elastin in the eyelid skin, there can still be IgA deposits around the remaining elastin fibers (Fuchs, Br J Dermatol 1996).
• The loss of elastin is not due to reduction in production by fibroblasts.
• Reverse transcriptase polymerase chain reaction performed on eyelid skin with marked loss of elastin still shows fibroblasts expressing normal levels of mRNA for elastin production (Kaneoya, J Dermatol 2005).

Staging

• There is no staging for this disease.
• Active phase is differentiated from atrophic or quiescent phase.

• Mostly sporadic disease with some genetic predisposition
• A wide range of triggers have been reported, but most cases have no known triggers.
• Reported triggers include
• Menstruation
• Fatigue
• URI
• Bee sting
• Lymphocytic leukemia
• Physical or mental stress

• Allergic recurrent angioedema (Garcia-Ortega, Allergy 2003)
• Blepharochalasis is easily mistaken for recurrent allergy and many patients undergo skin and patch testing and even allergy shots unnecessarily.
• The absence of systemic involvement including swelling of the extremities, pruritis, or urticaria should suggest the diagnosis.
• Unlike blepharochalasis, allergic angioedema is usually relieved by antihistamines and corticosteroids.
• Hereditary angioedema is a rare, life-threatening disorder that is important to differentiate from blepharochalasis (Walford, Ann Asthma Allerg Immunol 2014).
• Specifically associated with decreased C1 esterase inhibitor activity
• Further subdivided into quantitative decrease in enzyme level (type 1, about 85% of cases) versus qualitative decrease in activity (type 2, about 15%).
• Recurrent episodes of angioedema broadly affect the subcutaneous and mucosal surfaces of the face, extremities, gastrointestinal and genitourinary tracts, and oropharynx.
• Laryngeal involvement can be fatal.
• Mean age at onset is similarly 8–12 years.
• Episodes are more frequent than blepharochalasis, every 1–2 weeks if untreated.
• Attacks last longer than allergic or idiopathic recurrent angioedema, typically 72–96 hours.
• There is no response to antihistamines or corticosteroids.
• The edema is nonpitting with no urticaria.
• Inherited as autosomal dominant, some have no family history
• Serum C4 levels are low, in contrast to normal levels with allergic angioedema (normal C4 during an attack essentially rules out the diagnosis of hereditary angioedema).
• Subcutaneous ecallantide is approved by the FDA for hereditary angioedema, to be administered with early onset of symptoms.
• An inhibitor of the protein kallikrein, the usual target of C1 esterase inhibitor
• Kallikrein is a protease that converts kininogen to bradykinin, which leads to fluid leakage from blood vessels.
• Dermatochalasis: seen in older people with redundant eyelid skin
• Contact dermatitis: Consider allergic patch testing.
• Aponeurotic or mechanical ptosis
• Floppy eyelid syndrome
• Melkersson-Rosenthal syndrome:
• Recurrent triad of recurring oro-facial swelling, relapsing facial nerve palsy and lingua plicata

Natural history

• Develops usually insidiously around puberty
• Two phases have been recognized: hypertrophic or active, and atrophic or quiescent.

Medical therapy

• Systemic and topical corticosteroids, and antihistamines, have not proven efficacious.
• Doxycycline: Matrix metalloproteinases (MMP) are released in eyelid inflammation, leading to breakdown of elastin and collagen fibers. Doxycycline inhibits MMP synthesis. Two cases of blepharochalasis, a 16 and 21 year old, both with recent onset disease, remained symptom-free for 18 months and 8 months, respectively, after treatment with doxycycline (Karaconji, OPRS 2012).
• Oral acetazolamide (250 mg SR daily) in combination with hydrocortisone cream has been used in a small case series of six patients with reported efficacy, but these patients were older (37-78 years old) (Drummond, Orbit 2009).

Radiation

• None

Surgery

• Most recommend waiting until after active phase, if possible.
• Correction of ptosis: might need to reset the lid crease
• Blepharoplasty for redundant skin
• Resuspension of prolapsed lacrimal gland
• Repair of dehisced medial and lateral tendons

Other management considerations

• The presence of IgA around elastin fibers suggests an immune mechanism — and immune modulators might be of benefit — or the IgA deposition might be an epiphenomenon.
• The primary etiology of this disease is still not known.

Common treatment responses, follow-up strategies

• There is no specific treatment for this disease, other than reversing its effects once it is stable.
• If possible, avoid allergens and other triggering factors.

Lid retraction with lagophthalmos can occur after ptosis and blepharoplasty surgery because of extreme tissue laxity and scarring.

If blepharoplasty is indicated, remove fat sparingly because the late phase of the disease is associated with fat atrophy.

• Atrophy of eyelid structures
• Prominent eyelid vascularity
• Keratopathy due to eyelid malposition, lagophthalmos and misdirected eyelashes

Blepharochalasis was first described by Fuchs in 1896 as recurrent episodes of painless eyelid edema and thinning of the skin (Wien Klin Wchnschr. 1896;9:109).

In 1920, Ascher described a syndrome of blepharochalasis together with a double lip (mostly the upper lip) and nontoxic goiter (Klin Monatbl Augen 1920; 65:86; Br J Plast Surg 1981; 34:31).

1. AAO, Basic and Clinical Science Course. Section 7: Orbit, Eyelids, and Lacrimal System, 2010-11.
2. Ascher KW: Blepharochalasis mit struma and doppellipe. Klin Monat Augen 1920; 65:86.
3. Bartley GB, Gibson LE, Blepharochalasis associated with dermatomyositis and acute lymphocytic leukemia. Am J Ophthalmol 1992; 113:727.
4. Benedict WL. Blepharochalasis. JAMA. 1926; 87: 1735-1739.
5. Bergin DJ, McCord CD, Berger T, et al. Blepharochalasis. Br J Ophthalmol 1988; 72:863.
6. Collin JR. Blepharochalasis. A review of 30 cases. Ophthal Plast Reconstr Surg 1991; 7:153.
7. Custer PL, Tenzel RR, Kowalczyk AP. Blepharochalasis syndrome. Am J Ophthalmol 1985; 99:424-428.
8. Drummond SR, Kemp EG: Successful medical treatment of blepharochalasis: a case series. Orbit 2009; 28:313.
9. Frigas E, Park M. Idiopathic recurrent angioedema. Immunol Allergy Clin North Am. 2006;26:739-751.
10. Fuchs E. Ueber Blepharochalasis. Wien Klin Wchnschr. 1896;9:109.
11. Garcia-Ortega P, Mascaro F, Corominas M, Carreras M: Blepharochalasis misdiagnosed as allergic recurrent angioedema. Allergy 2003; 58:1197.
12. Grassegger A, Romani N, Fritsch P, et al. Immunoglobulin A (IgA) deposits in lesional skin of a patient with blepharochalasis. Br J Dermatol 1996;135:791.
13. Hallahan KM, Sood A, Singh AD: Acute episode of eyelid oedema. Br J Ophthalmol 2012; 96:909.
14. Huemer GM, Schoeller T, Wechselberger G, et al. Unilateral blepharochalasis. Br J Plast Surg 2003; 56:293.
15. Hundal KS, Mearza AA, Joshi N. Lacrimal gland prolapse in blepharochalasis. Eye 2004; 18:429-430.
16. Jordan DR. Blepharochalasis syndrome: a proposed pathophysiologic mechanism. Can J. Ophthalmol 1992; 27:10.
17. Kaneoya K et al. Elastin Gene Expression in Blepharochalasis. J Dermatol 2005; 32:26
18. Karaconji T, Skippen B, Di Girolamo N, et al: Doxycycline for treatment of blepharochalasis via inhibition of matrix metalloproteinases. Ophthal Plast Reconstr Surg 2012; 28:e76.
19. Koursh MD, Modjtahedi SP, Selva D, Leibovitch I. The blepharochalasis syndrome. Surv Ophthalmol 2009; 54:235.
20. Langley KE, Patrinely JR, Anderson RL, Thiese SM. Unilateral blepharochalasis. Ophthalmic Surg 1987;18:594.
21. Li D, Chen T, Hou Z, Li Y: Clinical features of blepharochalasis and surgical treatment of associated deformities. Chinese J Ophthalmol 2012; 48:696.
22. Rintala AE: Congenital double lip and Ascher syndrome: II. Relationship to the lower lip sinus syndrome. Br J Plast Surg 1981; 34:31.
23. Tenzel RR, Stewart WB: Blepharo-confusion: blepharochalasis or dermatochalasis. Arch Ophthalmol. 1978;96:911.
24. Walford HH, Zuraw BL: Current update on cellular and molecular mechanisms of hereditary angioedema. Ann Asthma Allerg Immunol 2014; 112:413.
25. Wang G, Li C, Gao T: Blepharochalasis: A rare condition misdiagnosed as recurrent angioedema. Arch Dermatol 2009; 145:498.